Our top pick for
PolarityTE, Inc is a biotechnology business based in the US. PolarityTE shares (PTE) are listed on the NASDAQ and all prices are listed in US Dollars. PolarityTE employs 153 staff and has a trailing 12-month revenue of around USD$8 million.
|52-week range||USD$0.5911 - USD$2.38|
|50-day moving average||USD$1.2762|
|200-day moving average||USD$1.0251|
|Wall St. target price||USD$3|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-4.842|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$8 million|
|Gross profit TTM||USD$3.2 million|
|Return on assets TTM||-56.09%|
|Return on equity TTM||-140.2%|
|Market capitalisation||USD$97.5 million|
TTM: trailing 12 months
There are currently 4.0 million PolarityTE shares held short by investors – that's known as PolarityTE's "short interest". This figure is 2.4% up from 3.9 million last month.
There are a few different ways that this level of interest in shorting PolarityTE shares can be evaluated.
PolarityTE's "short interest ratio" (SIR) is the quantity of PolarityTE shares currently shorted divided by the average quantity of PolarityTE shares traded daily (recently around 11.6 million). PolarityTE's SIR currently stands at 0.34. In other words for every 100,000 PolarityTE shares traded daily on the market, roughly 340 shares are currently held short.
However PolarityTE's short interest can also be evaluated against the total number of PolarityTE shares, or, against the total number of tradable PolarityTE shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case PolarityTE's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 PolarityTE shares in existence, roughly 60 shares are currently held short) or 0.0686% of the tradable shares (for every 100,000 tradable PolarityTE shares, roughly 69 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against PolarityTE.
Find out more about how you can short PolarityTE stock.
We're not expecting PolarityTE to pay a dividend over the next 12 months.
PolarityTE's shares were split on a 1:6 basis on 1 August 2016. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your PolarityTE shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for PolarityTE shares which in turn could have impacted PolarityTE's share price.
Over the last 12 months, PolarityTE's shares have ranged in value from as little as $0.5911 up to $2.38. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while PolarityTE's is 1.1254. This would suggest that PolarityTE's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
PolarityTE, Inc., a biotechnology and regenerative biomaterials company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine and Contract Services. It offers SkinTE, a tissue product for treatment of defects of the skin, as well as contract research services; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and PTE 11000, an allogenic, biologically active dressing for use in wound care and aesthetics to accelerate healing of skin. The company also develops OsteoTE, an autologous homologous bone regeneration product; and CartTE, an autologous cartilage regeneration product. In addition, it develops AdipoTE to optimize the delivery of autologous fat; AngioTE for vascular regeneration; NeuralTE for peripheral nerve injuries of the extremities, as well as for patients with neuromas or chronic compression due to joint replacements, migraines, craniofacial injuries, carpal tunnel syndrome, and those who have undergone hernia or abdominal-based procedures; UroTE for the delivery of autologous urogenital epithelium and submucosa; LiverTE to address various causes of liver failure; and BowelTE to deliver an optimized autologous construct to aid in the regeneration of bowel tissue. PolarityTE, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.